To test this hypothesis, we employed an adenoviral delivery system to restore the lower levels of ASK1/TGF-β/p53 signaling in obese mice and analyzed the effect of Smads on obesity-associated metabolic abnormalities in HFD-fed mice. The gene discussed is TP53; the disease is obesity disorder.